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Atrial fibrillation (AF) is the commonest of all sustained arrhythmias, and most of the patients seeking medical therapy are in
the elderly age group. The management of these patients is particularly difficult due to associated comorbidities. Hypertension,
congestive heart failure, left ventricular hypertrophy, and coronary artery disease are often present in the elderly patient population,
and therefore, antiarrhythmic drugs often fail due to side effects, proarrhythmia, or poor rhythm control. Recently, radiofrequency
catheter ablation has been widely performed as an efficient therapy for recurrent, drug-refractory AF. Nevertheless, patients at
old age were underrepresented in prior AF ablation trials, and the current guidelines for catheter ablation of AF recommend a
noninvasive approach in the elderly patient group due to the lack of clinical data supporting ablation therapy. However, study
results of our group and others are suggesting that catheter ablation is a safe and effective treatment for patients over the age
of 65 years with symptomatic, drug-refractory AF, and therefore, patients should not be precluded from catheter ablation only
on the basis of age. This paper discusses the pharmacological (rhythm control, rate control, and anticoagulation) and catheter
management of AF in the elderly population.
1. Introduction
Atrial fibrillation (AF) is the commonest of all sustained
arrhythmias, and its prevalence has been increasing. AF
confers an important mortality and morbidity outcome
from thromboembolism, stroke, heart failure, and significant
impairment of quality of life [1, 2]. The prevalence of AF
is more prominent with advanced age. About 8 to 10% of
people aged over 80 years are suffering from AF [3]. The
median age of an AF patient is 75 years, and 70% of the
AF patients are 65 to 85 years of age [4, 5]. Within the next
twenty to thirty years, the number of patients suffering from
AF is expected to double or triple due to an increased AF
incidence and aging of the populations in developed western
countries (Figure 1) [5, 6].
In former days, the management of AF focused on
preventing thromboembolism and controlling heart rate
or rhythm. The risk of stroke is increased 5-fold by AF.
AF is responsible for around 10–20% of all strokes. In
patients age groups 80 to 89 years, this proportion is even
more accentuated and around 25% [7]. Strokes related to
AF result often in higher mortality and morbidity rates.
The use of oral anticoagulation therapy is an important
intervention in preventing AF-related ischemic events. But
older people have both higher risk for stroke if not taking oral
anticoagulants and higher risk for bleeding with the use of
oral anticoagulants [8]. Therefore, the recommendation for
anticoagulation is a challenging task for the clinician treating
patients with AF in the old age. Disease management is also
particularly challenged by comorbidities including hyperten-
sion, congestive heart failure, left ventricular hypertrophy,
coronary artery disease, and diabetes mellitus which are
frequently present in this patient age group. These comor-
bidities also confer an increased risk for thromboembolic
complications or drug-related side effects [9]. Moreover,
other endpoints such as left ventricular and atrial function,
quality of life, social functioning, silent cerebral embolism
and dementia are novel targets of comprehensive AF disease
management [10].
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Figure 1: Projected number of adults with AF in the United States
between 1995 and 2050 from the ATRIA study (the AnTicoagulation
and Risk Factors in Atrial Fibrillation Study) [5].
Ablation therapy has emerged as an efficient intervention
for recurrent, drug-refractory AF [11–14]. Current ablation
techniques have improved, and the complication rates have
decreased resulting in increasing number of referrals of
patients of old age for catheter ablation of AF [15–18].
Nevertheless, a minority of elderly patients were included
in prior AF ablation trials. Friable cardiac structures, which
may be at risk for catheter perforation, long procedure times,
and the associated comorbidities, are frequently considered
to confer an increase of overall peri- and postprocedural
risk. For that reason and in the absence of clinical data, the
recommendation in the guidelines for catheter ablation of
AF advices a conservative approach in patient populations of
old age [19]. Nevertheless, with advanced life expectancy, the
elderly population group is a rapidly expanding portion of
our community making AF an even more important public
health concern. Catheter ablation could become a pivotal
treatment strategy in the elderly patient population after
failure of antiarrhythmic drugs.
2. Stroke Prevention in the Elderly
Oral vitamin K antagonists efficiently reduce the risk of
cerebrovascular embolism in elderly AF patients as clearly
shown in several randomized trials [20, 21]. Patients with
AF aged over 75 years have a thromboembolic complication
risk of over 4% per year, mandating therapy with oral
vitamin K antagonists unless there is a significant risk for
major bleeding present. Among each components of the
widespread CHADS2 (cardiac failure, hypertension, age,
diabetes, and stroke (doubled)) risk score, age ≥ 75 years
confers an impaired prognosis for stroke and mortality over
hypertension, heart failure, or diabetes [22]. Therefore, the
CHADS2 score was extended recently to the CHA2DS2-VASc
score by considering additional risk factors such as vascular
disease (i.e., priormyocardial infarction), age between 65 and
74 years, and female sex (Table 1) [23]. The risk for stroke can
be reduced by oral vitamin K antagonists by about 70% and
Table 1: Stroke risk assessment in nonvalvular AF: CHA2DS2-VASc
[23]. For a CHA2DS2-VASc score > 1, such patients are high risk,
and oral anticoagulation is recommended; for a CHA2DS2-VASc
= 1, either oral anticoagulation or apirin 75 to 325mg daily is
recommended, but oral anticoagulation is preferred rather than
aspirin; for a CHA2DS2-VASc = 0, either aspirin 75 to 325 mg daily
or no antithrombotic treatment can be used, but no antithrombotic
therapy is preferred.
Risk factors Score
Congestive heart failure/LV dysfunction 1
Hypertension 1
Age ≥ 75 years 2
Diabetes mellitus 1
Stroke/TIA/TE 2
Vascular disease (prior MI, PAD, or aortic plaque) 1
Age 65–74 years 1
Sex category (i.e., female sex) 1
Maximum score 9
TIA: transient ischemic attack; TE: thromboembolic event.
consecutively the mortality by 33% [24]. But, these agents
have a small therapeutic window with an associated hem-
orrhagic risk complicating anticoagulation management. In
general, the anticoagulation intensity should be optimized by
keeping the international normalized ratio (INR) between
2.0 and 3.0 [25]. Several studies have shown that low
fixed-dose use of an oral vitamin K antagonist or targeting
lower INRs (<2.0) in older patient groups increase the risk
for stroke without protecting against intracerebral bleeding
[25–27]. In cases where oral vitamin K antagonists are
contraindicated, antiplatelet therapy with aspirin provides
some prevention from cerebrovascular embolism, but much
less efficiently than oral vitamin K antagonists [28]. Aspirin
reduces the risk for stroke by about 20%. Interestingly, the
beneficial effect of antiplatelet therapy on ischemic stroke
appears to diminish with increasing age and is no longer
present after the age of 77 years [29, 30]. Warfarin was
found to be superior to combined therapy with clopidogrel
plus aspirin with similar rates of bleeding complications
in the Atrial fibrillation Clopidogrel Trial with Irbesartan
for prevention of Vascular Events (ACTIVE-W) study [31].
A novel generation of oral anticoagulants is emerging and
being approved for AF such as dabigatran, an oral direct
thrombin inhibitor. In a large randomized trial (Randomized
Evaluation of Long-Term Anticoagulation Therapy; RE-LY),
dabigatran has shown to be superior to warfarin in terms
of similar reduction of stroke rates, but lower rates for
major bleeding [32]. Apixaban, a novel factor Xa inhibitor,
was superior to aspirin for reduction in stroke without
increase of major bleeding in 5599 patients (mean age of 70
years), who are unsuitable for vitamin K antagonist therapy,
as reported in the AVERROES trial [33]. Elderly patients
are less likely than younger patients to receive appropriate
anticoagulation and are more likely to have subtherapeutic
INR levels. In general practice, fewer than half of eligible
patients take warfarin [34, 35]. High fall risk, history of
bleeding, nonadherence, and dementia are the major factors
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preventing physicians to prescribe oral anticoagulants [36–
38]. Therefore, in elderly patients ineligible for vitamin
K antagonist therapy, oral direct thrombin or factor Xa
inhibitor, dabigatran, or apixaban, respectively, should be
considered as an effective and safe option.
3. Pharmacological Management in the Elderly
Several randomized trials comparing rhythm control versus
rate control in AF patients showed no evidence that the
clinical outcome of hospitalization, stroke, and mortality is
improved by restoration and maintenance of sinus rhythm
despite the clear relationship between AF and cardiovas-
cular events [39–44]. Moreover, rhythm control by phar-
macological interventions has been associated with higher
mortality in the elderly [40]. However, subgroup analyses
and the recent published outcome data of the ATHENA
trial signalize that safely maintained sinus rhythm by novel
antiarrhythmic drugs may prevent AF-related complications
[45, 46]. This placebo-controlled, double-blinded conducted
study assessed the efficacy of dronedarone for the prevention
of cardiovascular hospitalisation or death from any cause
in patients with AF and atrial flutter. Nevertheless, apart
from the effect of dronedarone on the composite endpoint
driven by cardiovascular hospitalizations in the ATHENA
trial, there are no controlled data available that show a
benefit of rhythm control therapy beyond improved quality
of life. The major studies on rhythm versus rate control
were the rate control versus electrical cardioversion (RACE)
trial [39], the atrial fibrillation follow-up investigation of
rhythm management (AFFIRM) trial [40], and the atrial
fibrillation congestive heart failure (AF-CHF) trial [43].
There was also a series of smaller studies performed, includ-
ing the pharmacological intervention in atrial fibrillation
(PIAF) [44], strategies of treatment of atrial fibrillation
(STAF) [41], and how to treat chronic atrial fibrillation
(HOT CAFE´) [42]. These studies have shown that primary
rate control is not inferior to rhythm control. Therefore,
first-line therapy in the elderly patient population with
symptomatic AF is usually a primary rate control approach.
Betablockers, nondihydropyridine calcium channel blockers,
and digoxin are widely used to control the ventricular rate
response in AF [35]. Digoxin can be added if impaired left
ventricular systolic function is present, but caution should
be raised because of potential drug toxicity, especially in
elderly patients with frequent impaired renal function and
polypharmacy. Previous guidelines recommended targeting
a resting heart rate of less than 80 beats per minute. But a
recent randomized trial showed no clinical benefit of a strict
rate control versus a lenient rate control targeting resting
heart rates of about 115 beats per minute in terms of clinical
cardiovascular events [47]. Antiarrhythmic drugs with the
aim to maintain sinus rhythm may be considered, if patients
remain symptomatic despite optimal rate control, but the
increased risk for proarrhythmia, drug interactions, and age-
related comorbidities in the elderly population should be
carefully taken into account. Class Ic antiarrhythmic drugs,
flecainide, and propafenone have shown to increase mor-
tality in patients with coronary artery disease [48]. Sotalol
Table 2:Major complication rates in a worldwide survey of catheter
ablation for AF in 16,309 patients from Cappato et al. [56].
Type of complication Rate, %
Death 0.15
Tamponade 1.31
Pneumothorax 0.09
Hemothorax 0.02
Sepsis 0.01
Phrenic nerve palsy 0.17
Femoral pseudoaneurysm 0.93
Arteriovenous fistulae 0.545
Valve damage/requiring surgery 0.07
Atrio-esophageal fistulae 0.04
Stroke 0.23
Transient ischemic attack 0.71
PV stenoses requiring intervention 0.29
Total 4.54
PV: pulmonary vein.
1.53
R
PA
+
−
Figure 2: Three-dimensional reconstruction (yellow) of the
computed tomography imaging and three-dimensional electro-
anatomical map (grey) of the left atrium in posteroanterior pro-
jection with circumferential ablation (red points) around ipsilateral
pulmonary veins using CARTO system (Biosense Webster Inc.,
Diamond Bar, Calif, USA).
and dofetilide should not be used in patients with renal
impairment. Amiodarone is the most effective drug and safe
in heart failure patients, but regular follow-up of thyroid,
hepatic, and pulmonary function is mandatory because of
frequent extracardiac drug toxicity. Therefore, amiodarone
should be reserved for use if other antiarrhythmic drugs have
failed or are contraindicated.
4. Catheter Ablation of AF in the Elderly
An effective alternative option for drug-refractory AF with
a rapid ventricular rate response is the transvenous catheter
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Table 3: Catheter ablation of AF in the elderly.
Haegeli et al. [57] Bunch et al. [58] Tan et al. [59] Zado et al. [60]
Inclusion age (years) ≥65 ≥80
≥80 65–74
70–79 ≥75
60–69
Mean age (years) 69± 3.5 82± 2
84± 5 68± 3
75± 4 77± 2
66± 4
Number of patients 45 35
49 185
151 32
177
Number of procedures 53 35
53 228
174 34
209
Paroxysmal AF (%) 87 46
55 62
53 53
51
Ablation strategy
PVI ± linear PVI ± linear PVI PVI
lesions Lesions
Mean F/U (months) 6 12 18 27
Periprocedural complication rate (%)
(i) Pericardial tamponade 1.9 2.8 0.2 0.4
(ii) Deep venous thrombosis 0 2.8 0.9 0
(iii) CVA/TIA 0 0 0.7 0.8
(iv) Retroperitoneal bleeding 0 0 0.7 0.4
(v) Pseudoaneurysm/AV fistula 030 0 0.5 2.7
Freedom of AF 74% 78%
70% 84%
72% 86%
74%
PVI: pulmonary vein isolation; CVA: cerebral vascular accident; TIA: transient ischemic attack.
ablation of the atrioventricular node and the placement of
a permanent pacemaker. The procedure is associated with
minimal mortality and morbidity, but this approach does
not eliminate AF and the need for anticoagulation [49].
Pathophysiological knowledge that focal sources of ectopic
beats arising from the pulmonary veins often initiate AF
has lead to the development of catheter ablation for AF
in the last decade [11]. The majority of ablation strategies
currently used involves circumferential ablation around the
ostia of the ipsilateral pulmonary veins with the endpoint
of electrical isolation of the pulmonary veins from the left
atrium [50–52]. Success rates approach 70% to 90% in
experienced centers [53]. However, most of the published
data are obtained in younger patients aged below 65 years
and without heart disease and comorbidities. Catheter
ablation for chronic AF is less successful than for paroxysmal
AF and is associated with higher complication rates in
older patients having structural heart disease [14, 54, 55].
Procedure-related complication rates were reported in a large
worldwide multicenter survey and are listed on Table 2
[17]. In a retrospective analysis of 641 consecutive ablation
procedures, the rate for major complications was 5%, and
the age greater than 70 years was identified as a significant
predictor with an odds ratio of 3.7 [18].
In a recently published study, we reported the clinical
outcome of 45 consecutive patients over the age of 65 years
who underwent a percutaneous catheter ablation procedure
for symptomatic paroxysmal and persistent AF [57]. Among
them, none had a significant structural heart disease. All
patients underwent wide-area circumferential pulmonary
vein isolation for paroxysmal AF with additional linear
lesions for persistent AF. The ablation was performed point
by point by radiofrequency energy and guided by a three-
dimensional electroanatomical mapping system (Figure 2)
[61]. The endpoint of the procedure in both paroxysmal
and persistent AF patients was electrical isolation of all
pulmonary veins, which was assessed using a circular spiral
catheter. Our results suggested that catheter ablation of AF
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AV, atrioventricular; NYHA, New York heart association class; LVH, left ventricular hypertrophy
AF in the elderly
Rate control
• Consider AV node ablation and pacemaker implantation
for elderly patients with structure heart disease and difficult rate control
Rhythm control
No or minimal heart disease:
Dronedarone Dronedarone
Dronedarone
Dronedarone
Flecainide
Propafenone
Sotalol
Structural heart disease:
•Heart failure NYHA I/II
• Coronary artery disease
• LVH
Amiodarone
Catheter ablation
sotalol
• AV node-blocking agents
Figure 3: Decision tree for the therapy of AF in the elderly integrating pharmacological treatment and catheter ablation, modified from the
guidelines for the management of AF proposed by the European Society of Cardiology [63].
in elderly patients can be performed with success rates
comparable to those in younger patients without an increase
in complication rate. Successful maintenance of a stable sinus
rhythm could be achieved in nearly 80% of this patient
cohort with a mean age of 69 years (Table 3). Zado et al.
found similar success and complication rates in patients over
65 years of age [60]. Patients over the age of 80 years in
the paper of Tan et al. were less likely to undergo a repeat
procedure than younger patients. However, the success and
complication rates were not significantly different in the age
group over 80 years than in those 60–69 years (70% versus
74% for success rate) [59]. Similarly, the study reported
by Bunch et al. found no increased risk of periprocedural
complications in patients aged 80 years and older [58].
Available published outcome data for catheter ablation in the
elderly population were derived from observational cohort
analysis with a follow-up period of up to two years with
procedural success defined as freedom from symptomatic AF.
A long-term follow-up study reported that the success rate
in 100 patients was 63% at 5 years after a median of two
procedures per patient [62]. Prospective, randomized trials
comparing an invasive versus a conservative pharmacological
approach are required to address the remaining questions on
best management of AF in the elderly population. A decision
tree integrating different choices of rate and rhythm control
and pharmacological therapy versus catheter ablation of AF
in this selected elderly patient population is proposed in
Figure 3 based on the current guidelines of the European
Society of Cardiology [63].
5. Conclusion
Elderly patients differ considerably from patients in the
younger age group as they have a higher incidence of
AF associated with a higher thromboembolic risk due
to advanced age and frequent multiple comorbidities. In
addition, the adverse side effects of antiarrhythmic drugs,
such as proarrhythmia, are more commonly observed in
the elderly patient population. Nonrandomized studies in
patients aged 65 years and more with symptomatic drug-
refractory AF have shown that catheter ablation can be
performed with comparable safety and efficiency as with
younger patients. Therefore, ablation therapy may be con-
sidered as an appropriate therapeutic option also for the
older group of patients if antiarrhythmic drug treatment
fails. Patients should not be precluded from undergoing AF
catheter ablation exclusively on the basis of age.
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